David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Gear Up for a Historic Test Flight With Virgin Galactic Stock

By David Moadel, InvestorPlace Contributor

Is the recent ramp-up in SPCE stock justified? With Richard Branson's start-up about to send people into space, the answer is a definite yes.

Avoid Tilray Stock While Shares Are Fueled by Political FOMO

By David Moadel, InvestorPlace Contributor

It's fine to anticipate positive developments in the broader cannabis market, but loading up on Tilray stock isn't the best move now.

Own Hexo Shares for the Value-Added Cannabis Brands

By David Moadel, InvestorPlace Contributor

In the world of cannabis products, it's all about the branding. Hexo stock should rise as the company profits from superior-quality offerings.

Keep Your Long-Term Expectations Low With Boeing

By David Moadel, InvestorPlace Contributor

It's tempting to go all-in on Boeing stock in light of progress on the Covid-19 vaccine front, but it's smart to maintain a cautious outlook.

Amazon’s Pharmacy Push Is Bad News for GoodRx Stock

By David Moadel, InvestorPlace Contributor

It's understandable if you believe in GoodRx's vision of pharmacy-market disruption, but holding on to GoodRx stock is a risky proposition.

Load More